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ABSTRACT 
 
This study describes the clinical characteristics and examines hospital costs involved in the care 
of 117 patients undergoing Continuous Renal Replacement Therapy (CRRT) between January 
1999 and August 2002. The majority (70.9%) of the patients undergoing CRRT expired in the 
hospital. Statistically significant differences were found with respect to length of stay for 
discharge status and gender; and with respect to costs for surgery versus no surgery and gender. 
Significant differences also were found between discharge status and gender, age, and 
cardiovascular surgery. The results of this study raise economic and ethical questions related to 
the cost/benefit of CRRT and futility of the treatment. Hospitals should ensure that they have 
utilization protocols in place for CRRT, promote cooperation between ICU physicians and 
nephrologists, and create multidisciplinary CRRT teams in an effort to maximize the 
effectiveness of therapy and minimize costs. 
______________________________________________________________________________ 
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INTRODUCTION 
Continuous renal replacement therapy (CRRT) is the preferential mode of therapy for 
various critical conditions due to its safety and efficiency (Ronco and Bellomo, 1998). Among 
the different types of CRRT techniques are continuous arteriovenous hemofiltration (CAVH), 
continuous arteriovenous hemodialysis (CAVHD), continuous arteriovenous hemodiafiltration 
(CAVHDF), slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration 
(CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous 
hemodiafiltration (CVVHDF) (Brush and Bilodeau, 2001). 
CRRT as renal replacement therapy has some advantages.  Perhaps the most important 
advantage is that this therapy is considered appropriate for intensive care unit/critical care unit 
(ICU/CCU) patients, given the continuous process involved in the regulation or removing of 
fluids (Dirkes 2000 and Kellum et al., 2002). Although CRRT may be beneficial in the treatment 
of a number of conditions, there are also disadvantages that are associated with its use.   The cost 
and time of pharmacies in the preparation of solutions for the replacement of fluids depending on 
the specific needs of the patient and different groups of physicians with different protocols of 
treatment is one concern (Dirkes, 2000). Additional cost concerns include the labor of ICU 
nurses due to high (1:1 or 2:1) staffing requirements. Differences in cost also have been observed 
when various CRRT techniques have been compared. For example, increased cost and 
complexity have been linked to CVVH and CVVHD techniques. This is primarily due to 
equipment requirements, as compared to CAVH and CAVHD (Vanholder, Van Biesen and 
Lameire, 2001). 
The higher cost related to CRRT is one of the factors restricting its use, even when 
differences are classified as minimal when compared to intermittent hemodialysis (Bellomo and 
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Ronco, 1999). The importance of CRRT use for the treatment at end of life, as well as the cost 
concerns related to this technique, prompted us to conduct a cost analysis study. The purpose of 
the study was to describe the demographic and clinical characteristics and hospital costs involved 
in the care of patients undergoing CRRT at one Texas hospital and discuss the ethical 
implications of applying high technology at this stage of life. 
METHODS 
Patients receiving CRRT between January 1999 and August 2002 at a Texas hospital 
were identified using the hospital’s clinical and accounting system. Data without identifiers were 
provided by the hospital’s Quality Management department. Variables of study were age, 
gender, race/ethnicity, hospital length of stay, hospital discharge status, surgery, Cardio Vascular 
Surgery (CVS) and hospital estimated costs. Costs were estimated at 33% of hospital charges 
based on Friedman et al. (2002) in which costs for investor-owned hospitals of 100+ beds are 
shown to range from 33% to 64% of charges. T-tests were used to assess differences between 
hospital length of stay and estimated costs with patient characteristics, including gender, age 
(<65 versus 65+), discharge status (alive versus expired), surgery versus no surgery, CVS versus 
no CVS and race/ethnicity. Pearson Chi Square was used to assess differences between patient 
characteristics (age, discharge status, gender, surgery versus no surgery, CVS versus no CVS and 
race/ethnicity) were also analyzed.  This study protocol sought and received appropriate 
approvals related to the protection of human subjects from the Institutional Review Board of the 
University of North Texas Health Science Center. 
RESULTS 
One hundred seventeen patients underwent CRRT during the study period. Most of them 
(59.8%) were 65 years and older. Females were more frequently observed (56.4%) and 59% of 
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patients were self-classified as non-Hispanic White, 25.6%, non-Hispanic Black, and 13.7% 
Hispanic (Table 1). Discharge disposition ranged from expired (71.8%) to home (11.1%), long 
term acute care (8.5%) transfer to another facility (4.3%) and hospice/home health (4.3%). The 
majority (62.3%) of the patients who underwent CRRT also had a surgical procedure, with 41% 
having surgery other than CVS, 16.2% having only CVS, and 5.1% having CVS along with other 
surgery (Table 1). 
 
Table 1 about here 
 
Table 2 shows patient with CRRT and their Length of Stay (LOS) by gender, being older 
than 65 years, discharge disposition, having surgery, having Cardio Vascular Surgery (CVS) and 
ethnic/ racial classification. The mean age of patients was 64.8 years with a range between 27 
and 96 years. The average length of hospital stay was 17 days, ranging from 1 to 74 days.  The 
LOS was statistically significant higher with being female, and patients which were discharge 
alive with 19.8 and 23. 3 days respectively, (p<0.05) (Table 2).  
 
Table 2 about here 
 
Three patients with total costs of $150,000 or greater were excluded from the analysis, as 
they were identified as outliers based on cost. Average estimated costs, based on 33% of total 
hospital charges, were $50,762, with a range of $3,518 to $147,856. The estimated cost was 
statistically significant higher with being female and having surgery with $ 56,407 and $56,006 
respectively and (p<0.05) (Table 3). 
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Table 3 about here 
 
More females less than 65 years old were discharge alive (p< 0.05) and not having 
cardiovascular surgery was found   to be statistically significant (p< 0.05). In addition more 
indiviuals who were younger than 65 years old were found to be discharge alive from the 
hospital (p< 0.05) (Table 4). 
 
Table 4 about here 
 
DISCUSSION AND CONCLUSION 
 
The statistically significant difference observed between length of stay and discharge 
status suggests that those who expire do so early in the hospitalization and those who survive 
have longer lengths of stay. Females were found to have a longer length of stay and better 
survival rate. The difference in survival based on gender (36.4% of females survived versus 
17.6% of males) may be explained by may be to an age difference between the gender groups. 
An analysis by gender and age indicated a significant difference between males and females (p = 
0.037).  Similarly, the significant difference between survival and age showed that patients 65 
years and older had a higher probability of not surviving. Based on the results of this analysis, 
we observed that among patients undergoing CRRT, increased costs were incurred for patients 
<65 years old that undergo surgery and who did not expire in the hospital. Being a female <65 
years old was associated with better survival. In addition, patients undergoing CVS had a greater 
risk of expiring in the hospital. 
Continuous renal replacement therapy (CRRT) continues to be a proven mode of therapy 
for various critical conditions due to its safety and efficiency. In this paper we reviewed the 
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demographic and clinical characteristics and hospital costs involved in the care of patients 
undergoing CRRT at one southwestern hospital. The statistically significant difference between 
estimated costs with individuals who had CVS compared to those without CVS was expected in 
that surgical procedures tend to increase cost. However, it is interesting that there was not a 
corresponding significant difference between length of stay and whether or not a patient had 
surgery, which suggests that surgery does not affect the length of stay. A minority of the patients 
who underwent CRRT were discharged to the home or other long term living arrangement. The 
statistically significant differences between discharge status and gender, age and CVS suggests 
further study to determine the cost/benefit of CRRT at the end of life. Clearly this raises ethical 
as well as economic questions in conjunction with the treatment decision making process. 
End of life decisions regarding the withdrawal or withholding of life support and futile 
care have become commonplace within the ICU/CCUs. The concept of futile care is 
controversial and difficult to define. Efforts to prolonging life once considered an outcome of 
healing may be viewed by some as harmful acts of prolonging suffering (Romesberg, 2003). The 
costs of futile care for the dying are enormous. Futility can present challenges because of the 
monetary cost of such care, its negative effect on staff members and the burden it creates on the 
patient family and the clinicians (Coppa, 1996). Zamperetti et al. (2000) reported in a study of 
the first international course of critical nephrology, that only 55% of nephrologists believed that 
informed consent was necessary for initiating CRRT and 25 % would start or maintain unwanted 
CRRT.  
In this study it was found two patients with a Do-Not-Resuscitate (DNR) who were 
connected to CRRT by the same nephrologists. One of these cases was referred to the hospital 
ethics committee and the only outcome was a recommendation to the critical care committee to 
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develop family conferences early in the patient process of dying. Both patients died and no 
changes were made in the ICU/CCU policies or in the behavior of the nephrologists, except not 
to connect DNR patients to CRRT. The American Medical Association Council on Ethics and 
Judicial Affairs recommends a process-based approach to futility determination, which includes 
all involved parties (AMA, 1999). I believe that early family conferences should by part of the 
EOL and should involve not only the nephrologists, but also the critical care physician of the 
ICU, nurses, social workers and case managers who are at the bedside. This multidisciplinary 
team should be equipped with the ethical knowledge and communication skills necessary to care 
for patients and families facing the ethical dilemmas of futile care. Consideration of futility 
during EOL did not receive adequate attention in this unit which incurred an additional human 
and material burden. According to Bellomo and Ronco (1999), the structural organization of 
both the ICU and the hospital is among the important variables related to cost in renal 
replacement therapy. Teamwork and effective communication between ICU/CCU physicians and 
nephrologists is vital for the adequate use of CRRT (Bellomo and Ronco 2000, Hansard and 
Haseeb 2001).  
CONCLUSIONS 
The creation of a CRRT team with specific functions and the development of detailed 
CRRT protocols are recommendations that could help in optimizing the use of the therapy and at 
the same time reducing costs. It is likely that hospitals may find the best cost/benefit ratio for 
CRRT using this approach. 
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Table 1: Demographic Characteristics, Discharge Status and Kind of Surgery of Patients 
Undergoing CRRT (n=117) 
Characteristic N     % 
Age Group     
< 65 47 40.2 
65+ 70 59.8 
Gender     
Female 66 56.4 
Male 51 43.6 
Race     
NHW* 69 59 
NHB** 31 26.5 
Hispanic 16 13.7 
Other 1 0.9 
Discharge 
Status 
    
Expired 84 71.8 
Home 13 11.1 
Transfer 4 3.4 
Nursing Home 1 0.9 
Long-term 
Acute Care 
10 8.5 
Home 
Health/Hospice 
5 4.3 
Surgery     
No surgery 44 37.6 
Non-CVS† 
with other 
surgery 
48 41 
CVS only 19 16.2 
CVS with 
other surgery 
6 5.1 
* Non Hispanic White, ** Non Hispanic Black 
† CVS = Cardiovascular surgery 
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Table 2: Length of Stay and demographic characteristics of individuals with CRRT with 
and without Cardiovascular Surgery 
Variable Group N Mean Std 
Dev 
t df p 
Length 
of Stay 
Female 66 19.83 15.089     0.007***  
Male 51 13.25 9.389 -2.73 115  
              
Age < 65 47 18.06 12.3 0.731 115 0.466 
Age 65+ 70 16.23 13.935 
              
Expired 84 14.46 11.104       
Living 33 23.33 16.159 3.396 115 0.001*** 
              
Surgery 73 16.85 11.922 -0.122 115 0.903 
No Surgery 44 17.16 15.414 
              
CVS† 25 12.76 9.536 1.803 115 0.074 
No CVS 92 18.11 13.949 
              
NHW 69 16.91 12.221 -0.428 98 0.67 
NHB 31 18.16 16.002 
              
NHW 69 16.91 12.221 0.65 83 0.517 
Hispanic 16 14.69 12.852 
              
NHB 31 18.16 16.002 0.751 45 0.457 
Hispanic 16 14.69 12.852 
* Non Hispanic White, ** Non Hispanic Black * **p < 0.05  
 † CVS = Cardio Vascular Surgery
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Table 3: Estimated Cost and demographic characteristics of individuals with CRRT with 
and without Cardiovascular Surgery 
  
    Mean 
Cost 
Std 
Dev 
t df p 
Estimated 
Cost 
Female 66 56407 35513     0.043*  
Male 51 43458 31743 -2.047 115  
              
Age < 
65 
47 53394 35752       
Age 65+ 70 48996 33588 0.677 115 0.5 
              
Expired 84 49507 31438       
Living 33 53958 41338 0.628 115 0.531 
              
Surgery 73 56006 34045       
No 
Surgery 
44 42064 33549 2.157 115 .033* 
              
CVS 25 47225 28090       
No CVS 92 51724 35987 0.578 115 0.564 
              
NHW 69 51662 32553       
NHB 31 51777 38770 -0.015 98 0.988 
              
NHW 69 51662 32553       
Hispanic 16 43901 35520 0.845 83 0.401 
              
NHB 31 51777 38770       
Hispanic 16 43901 35520 0.678 45 0.501 
* Non Hispanic White, ** Non Hispanic Black * **p < 0.05 
 † CVS = Cardiovascular surgery 
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Table 4:  Discharge Disposition by Gender, Age Status, Cardiovascular Surgery, and 
Having Surgery of Individuals with CRRT 
  Alive Expired Total χ2 df Sig 
Female 24 42 66 4.977  0.026* 
Male 9 42 51   1    
CVS† 30 62 92       
No 
CVS 
3 22 25 4.123 1 0.042* 
Age 
<65 
19 28 47       
Age 
65+ 
14 56 70 5.793 1 0.016* 
Surgery 18 55 73       
NS** 15 29 44 1.206 0.272 0.272 
  Age <65 Age 
65+ 
Total χ2   Sig 
Male 15 36 51       
Female 32 34 66 4.355 1 0.037* 
CVS 7 18 25       
No 
CVS 
40 52 92 1.96 0.162 0.162 
Surgery 32 41 73       
NS** 15 29 44 1.085 0.298 0.298 
  CVS No 
CVS 
Total χ2   Sig 
Male 11 40 51       
Female 14 52 66 0.002 0.963 0.963 
  Surgery No 
Surgery 
Total χ2   Sig 
Male 29 22 51       
Female 44 22 66 1.178 0.278 0.278 
* p < 0.05 ** NS= No Surgery  †CVS = Cardiovascular Surgery 
